Roivant reports positive trial results in non-infectious uveitis
- STAT reports that Roivant announced positive trial results for its immune drug in non-infectious uveitis.
- The result could open a new market for the drug beyond its current indications.
- Only the headline and lede were available to us; the specific endpoints and data are not confirmed here.
💡 Points
Uveitis is a small but sticky indication where a non-steroid oral option is valued, and another label extension spreads development cost across more indications. The market will want to see the effect size against the standard of care, not just the win itself. I'd expect this to feed straight into Roivant's partnering and financing narrative for the asset.
STAT+: Roivant says closely watched immune drug succeeded in new eye disease ↗